EZETROL® Re-examination Study (MK0653-175)(COMPLETED)
|ClinicalTrials.gov Identifier: NCT01070953|
Recruitment Status : Completed
First Posted : February 18, 2010
Results First Posted : November 4, 2011
Last Update Posted : October 14, 2015
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||4467 participants|
|Official Title:||Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of EZETROL® in Usual Practice|
|Study Start Date :||January 2005|
|Primary Completion Date :||July 2010|
|Study Completion Date :||July 2010|
EZETROL® 10 mg
Participants with Hypercholesterolemia treated with EZETROL®
- Participants With Any Clinical and/or Laboratory Adverse Experience While Being Treated With EZETROL® Within 14 Days After Treatment Discontinuation [ Time Frame: Up to 14 days after treatment discontinuation ]Participants who recieved EZETROL® and experienced any adverse event related or unrelated to EZETROL®, within 14 days after treatment.
- Mean Percent Change From Baseline to Treatment in Lipid Parameters [ Time Frame: Baseline to 4 weeks ]The mean percent change from baseline to treatment in lipid parameters (total cholesterol [TC], low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol, triglycerides[TG]) in participants who received EZETROL over 4 weeks and then had available laboratory results in Lipid Parameters.
- Overall Efficacy Evaluation of EZETROL® [ Time Frame: Baseline to 4 weeks ]Participants who received EZETROL over 4 weeks and then have been evaluated for overall efficacy assessment by investigator showing to be improved, unchanged or worsened.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01070953
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|